51
|
Apoptosis of osteosarcoma cultures by the combination of the cyclin-dependent kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor. Cell Death Dis 2013; 4:e566. [PMID: 23538447 PMCID: PMC3613821 DOI: 10.1038/cddis.2013.101] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Osteosarcoma (OS) is an aggressive bone cancer typically observed in adolescents and young adults. Metastatic relapse accounts primarily for treatment failure, and obstacles to improving cure rates include a lack of efficacious agents. Our studies show apoptosis of OS cells prepared from localized and metastatic tumors by a novel drug combination: SCH727965 (SCH), a cyclin-dependent kinase inhibitor, and NVP-AUY922 (AUY) or other heat shock protein 90 inhibitor. SCH and AUY induced apoptosis when added simultaneously to cells and when AUY was added to and removed from cells before SCH addition. Sequential treatment was most effective when cells received AUY for ~12 h and when SCH was presented to cells immediately after AUY removal. The apoptotic protein Bax accumulated in mitochondria of cotreated cells but was primarily cytosolic in cells receiving either agent alone. Additional data show that SCH and AUY cooperatively induce the apoptosis of other sarcoma cell types but not of normal osteoblasts or fibroblasts, and that SCH and AUY individually inhibit cell cycle progression throughout the cell cycle. We suggest that the combination of SCH and AUY may be an effective new strategy for treatment of OS.
Collapse
|
52
|
Fu J, Koul D, Yao J, Wang S, Yuan Y, Colman H, Sulman EP, Lang FF, Yung WKA. Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells. Cancer Res 2013; 73:3062-74. [PMID: 23492364 DOI: 10.1158/0008-5472.can-12-2033] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Genetic heterogeneity and signaling alterations diminish the effectiveness of single-agent therapies in glioblastoma multiforme (GBM). HSP90 is a molecular chaperone for several signaling proteins that are deregulated in glioma cells. Thus, HSP90 inhibition may offer an approach to coordinately correct multiple signaling pathways as a strategy for GBM therapy. In this study, we evaluated the effects of a novel HSP90 inhibitor, NVP-HSP990, in glioma tumor-initiating cell (GIC) populations, which are strongly implicated in the root pathobiology of GBM. In GIC cultures, NVP-HSP990 elicited a dose-dependent growth inhibition with IC50 values in the low nanomolar range. Two GIC subgroups with different responses were observed with an Olig2-expressing subset relatively more sensitive to treatment. We also showed that Olig2 is a functional marker associated with cell proliferation and response to NVP-HSP990, as NVP-HSP990 attenuated cell proliferation in Olig2-high GIC lines. In addition, NVP-HSP990 disrupted cell-cycle control mechanism by decreasing CDK2 and CDK4 and elevating apoptosis-related molecules. Mechanistic investigations revealed molecular interactions between CDK2/CDK4 and Olig2. Inhibition of CDK2/CDK4 activity disrupted Olig2-CDK2/CDK4 interactions and attenuated Olig2 protein stability. In vivo evaluation showed a relative prolongation of median survival in an intracranial model of GIC growth. Our results suggest that GBM characterized by high-expressing Olig2 GIC may exhibit greater sensitivity to NVP-HSP990 treatment, establishing a foundation for further investigation of the role of HSP90 signaling in GBM.
Collapse
Affiliation(s)
- Jun Fu
- Brain Tumor Center, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
53
|
Bussenius J, Blazey CM, Aay N, Anand NK, Arcalas A, Baik T, Bowles OJ, Buhr CA, Costanzo S, Curtis JK, DeFina SC, Dubenko L, Heuer TS, Huang P, Jaeger C, Joshi A, Kennedy AR, Kim AI, Lara K, Lee J, Li J, Lougheed JC, Ma S, Malek S, Manalo JCL, Martini JF, McGrath G, Nicoll M, Nuss JM, Pack M, Peto CJ, Tsang TH, Wang L, Womble SW, Yakes M, Zhang W, Rice KD. Discovery of XL888: A novel tropane-derived small molecule inhibitor of HSP90. Bioorg Med Chem Lett 2012; 22:5396-404. [DOI: 10.1016/j.bmcl.2012.07.052] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2012] [Revised: 07/09/2012] [Accepted: 07/12/2012] [Indexed: 01/01/2023]
|
54
|
Shi J, Van de Water R, Hong K, Lamer RB, Weichert KW, Sandoval CM, Kasibhatla SR, Boehm MF, Chao J, Lundgren K, Timple N, Lough R, Ibanez G, Boykin C, Burrows FJ, Kehry MR, Yun TJ, Harning EK, Ambrose C, Thompson J, Bixler SA, Dunah A, Snodgrass-Belt P, Arndt J, Enyedy IJ, Li P, Hong VS, McKenzie A, Biamonte MA. EC144 Is a Potent Inhibitor of the Heat Shock Protein 90. J Med Chem 2012; 55:7786-95. [DOI: 10.1021/jm300810x] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Affiliation(s)
- Jiandong Shi
- Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States
| | - Ryan Van de Water
- Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States
| | - Kevin Hong
- Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States
| | - Ryan B. Lamer
- Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States
| | - Kenneth W. Weichert
- Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States
| | | | | | - Marcus F. Boehm
- Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States
| | - Jianhua Chao
- Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States
| | - Karen Lundgren
- Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States
| | - Noelito Timple
- Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States
| | - Rachel Lough
- Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States
| | - Gerardo Ibanez
- Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States
| | - Christina Boykin
- Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States
| | - Francis J. Burrows
- Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States
| | - Marilyn R. Kehry
- Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States
| | - Theodore J. Yun
- Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States
| | - Erin K. Harning
- Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States
| | - Christine Ambrose
- Biogen Idec, 14 Cambridge
Center, Cambridge, Massachusetts 02142, United States
| | - Jeffrey Thompson
- Biogen Idec, 14 Cambridge
Center, Cambridge, Massachusetts 02142, United States
| | - Sarah A. Bixler
- Biogen Idec, 14 Cambridge
Center, Cambridge, Massachusetts 02142, United States
| | - Anthone Dunah
- Biogen Idec, 14 Cambridge
Center, Cambridge, Massachusetts 02142, United States
| | | | - Joseph Arndt
- Biogen Idec, 14 Cambridge
Center, Cambridge, Massachusetts 02142, United States
| | - Istvan J. Enyedy
- Biogen Idec, 14 Cambridge
Center, Cambridge, Massachusetts 02142, United States
| | - Ping Li
- Biogen Idec, 14 Cambridge
Center, Cambridge, Massachusetts 02142, United States
| | - Victor S. Hong
- Biogen Idec, 14 Cambridge
Center, Cambridge, Massachusetts 02142, United States
| | - Andres McKenzie
- Biogen Idec, 14 Cambridge
Center, Cambridge, Massachusetts 02142, United States
| | - Marco A. Biamonte
- Biogen Idec, 5200 Research Place, San
Diego, California 92122, United States
| |
Collapse
|
55
|
Centenera MM, Gillis JL, Hanson AR, Jindal S, Taylor RA, Risbridger GP, Sutherland PD, Scher HI, Raj GV, Knudsen KE, Yeadon T, Tilley WD, Butler LM. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clin Cancer Res 2012; 18:3562-70. [PMID: 22573351 DOI: 10.1158/1078-0432.ccr-12-0782] [Citation(s) in RCA: 88] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE Targeting Hsp90 has significant potential as a treatment for prostate cancer, but prototypical agents such as 17-allylamino-17 demethoxygeldanamycin (17-AAG) have been ineffective in clinical trials. Recently, a phase I study aimed at defining a biologically active dose reported the first response to an Hsp90 inhibitor in a patient with prostate cancer, which supports the development of new generation compounds for this disease. EXPERIMENTAL DESIGN The biological actions of two new synthetic Hsp90 inhibitors, NVP-AUY922 and NVP-HSP990, were evaluated in the prostate cancer cell lines PC-3, LNCaP, and VCaP and in an ex vivo culture model of human prostate cancer. RESULTS In cell lines, both NVP-AUY922 and NVP-HSP990 showed greater potency than 17-AAG with regard to modulation of Hsp90 client proteins, inhibition of proliferation, and induction of apoptotic cell death. In prostate tumors obtained from radical prostatectomy that were cultured ex vivo, treatment with 500 nmol/L of NVP-AUY922, NVP-HSP990, or 17-AAG caused equivalent target modulation, determined by the pharmacodynamic marker Hsp70, but only NVP-AUY922 and NVP-HSP990 showed antiproliferative and proapoptotic activity. CONCLUSIONS This study provides some of the first evidence that new generation Hsp90 inhibitors are capable of achieving biologic responses in human prostate tumors, with both NVP-AUY922 and NVP-HSP990 showing potent on-target efficacy. Importantly, the ex vivo culture technique has provided information on Hsp90 inhibitor action not previously observed in cell lines or animal models. This approach, therefore, has the potential to enable more rational selection of therapeutic agents and biomarkers of response for clinical trials.
Collapse
Affiliation(s)
- Margaret M Centenera
- Dame Roma Mitchell Cancer Research Laboratories and Adelaide Prostate Cancer Research Centre, University of Adelaide and Hanson Institute, Adelaide, Australia
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|